These findings suggest that ACKR3 is a potential therapeutic target for modulating depression and possibly pain, perhaps by inhibiting ACKR3, excess endogenous opioid peptides can remain in circulation and help to reduce neuroinflammation or alleviate pain. The gene discussed is ACKR3; the disease is depressive symptom measurement.